Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 1/2013

01-02-2013 | HIV/AIDS (R MacArthur, Section Editor)

Organ Transplantation and HIV Progress or Success? A Review of Current Status

Author: Alan Taege

Published in: Current Infectious Disease Reports | Issue 1/2013

Login to get access

Abstract

Advancements in the scientific understanding of human immunodeficiency virus (HIV) and care of those afflicted have progressed to make HIV a chronic disease and significantly extend the lives of HIV patients. Subsequently, an aging population has emerged, with the conditions inherent with advanced years, including organ failure. Organ transplantation is an accepted modality for organ failure; however, it was felt to be contraindicated in HIV patients because HIV was an ultimately fatal condition that would be hastened by additional immune suppression. Highly active antiretroviral therapy has dramatically altered that mind-set. After limited early experience and a recent large national trial, HIV organ transplantation has gained a degree of acceptance. This article will review the progress and unresolved issues.
Literature
1.
Pneumocystis Pneumonia—Los Angeles. CDC Morbidity and Mortality Weekly Report. June 5, 1981; 30(21).
2.
Weiss SH, Goedert JJ, Sarngadharan MG, et al. Screening test for HTLV-III (AIDS Agent) antibodies. Specificity, sensitivity, and applications. JAMA. 1985;253:221–5.PubMedCrossRef
3.
Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Eng J Med. 1998;338(13):853–60.CrossRef
4.
D:A:D Study. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Intern Med. 2006;166:1632–41.CrossRef
5.
Thio CL, Seaberg EC, Skolasky Jr R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.PubMedCrossRef
6.
Lesens O, Deschenes M, Steben M, et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus—positive hemophiliacs and should be treated as an opportunistic infection. J Inf Dis. 1999;179:1254–8.CrossRef
7.
Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Inf Dis. 2001;32:492–7.CrossRef
8.
Reisler RB, Han C, Burman WJ, et al. Grade 4 events in the era of HAART. J Aquir Immune Defic Syndr. 2003;34:379–86.CrossRef
9.
Fine DM, Perazella MA, Lucas GM, et al. Renal disease in patient with HIV infection. Drugs. 2008;68:963–80.PubMedCrossRef
10.
Kalayjian RC, Lau B. Mechekano et al.: Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012;26:1907–15.PubMedCrossRef
11.
Sreepada RTK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987;16:1062–8.
12.
Ortiz C, Meneses R, Jaffe D, et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int. 1988;34:248–53.PubMedCrossRef
13.
Perinbasekar S, Brod-Miller C, Pal S, et al. Predictors of survival in HIV-infected patients on hemodialysis. A J Nephro. 1996;16:280–6.CrossRef
14.
Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. A J Kid Dis. 2000;36:574–81.CrossRef
15.
Spengler U. Management of end-stage liver disease in HIV/hepatitis C virus co-infection. Cur Opin HIV AIDS. 2011;6:527–33.CrossRef
16.
Rubin RH, Jenkins RL, Shaw BW, et al. The acquired immunodeficiency syndrome and transplantation. Transplantation. 1987;44:1–4.PubMedCrossRef
17.
Rubin RH, Tokoff-Rubin NE. The problem of human immunodeficiency virus (HIV) infection and transplantation. Transplant Int. 1988;1:36–42.CrossRef
18.
Boyd AS. Organ Transplantation in HIV positive patients. N Eng J Med. 1990; 1492.
19.
Ciuffreda D, Pantaleo G, Pascua M. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation. Transplant Int. 2007;20:649–58.CrossRef
20.
Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. Transplantation. 1993;55:95–103.PubMedCrossRef
21.
Human immunodeficiency virus infection transmitted from an organ donor screened for HIV antibody-North Carolina. MMWR. 1987; 36:306–308.
22.
Feduska NJ, Perkins HA, Melzer J, et al. Observations relating to the incidence of AIDS and other possibly associated conditions in a large population of renal transplant recipients. Transplant Proc. 1987;19:2161–6.PubMed
23.
Kumar P, Pearson JE, Martin DH, et al. Transmission of human immunodeficiency virus by transplantation of a renal allograft with development of the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:244–5.PubMed
24.
L’Age-Stehr J, Schwarz A, Offermann G, et al. HTLV-III infection in kidney transplant recipients. Lancet II. 1985;1261.
25.
Margreiter R, Fuchs D, Hansen A, et al. HIV infection in renal allograft recipients. Lancet II. 1986; 398.
26.
Milgrom M, Esquenazi V, Fuller L, et al. Acquired immunodeficiency syndrome in a transplant patient. Transplant Proc. 1985;17 Suppl 2:75–6.
27.
Oliveira DBG, Winearls CG, Cohen J, et al. Severe immunosuppression in a renal transplant recipient with HTLV-III antibodies. Transplantation. 1986;41:260–2.PubMedCrossRef
28.
Prompt CA, Reis MM, Grillo FM, et al. Transmission of AIDS virus at renal transplantation. Lancet II. 1986; 672.
29.
Shaffer D, Pearl RH, Jenkins RL, et al. HTLV-III/LAV infection in kidney and liver transplantation. Transplant Proc. 1987;19:2176–80.PubMed
30.
Poli F, Scalamogna M, Pizzi C, et al. HIV Infection in Cadaveric renal allograft recipients in the North Italy transplant program. Transplantation. 1989;47:724–5.PubMedCrossRef
31.
Tzakis AG, Cooper MH, Dummer S, et al. Transplantation in HIV + patients. Transplantation. 1990;49:354–8.PubMedCrossRef
32.
Erice A, Rhame FS, Heussner RC, et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Inf Dis. 1991;13:537–47.CrossRef
33.
Swanson SJ, Kirk AC, Ko CW, et al. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transpl Inf Dis. 2002;4:144–7.CrossRef
34.
Ahuja TS, Zingman B, Glicklich D. Long-term survival in an HIV infected renal transplant recipient. Am J Nephro. 1997;17:480–2.CrossRef
35.
Antiretroviral therapy cohort collaboration. Life expectancy of individuals on combination antiretroviral therapy in high –income countries; a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–9.CrossRef
36.
Roland ME, Carlson L, Ragni M, et al. Solid organ transplantation in HIV-infected recipients: forty-seven cases in the HAART era. Int Conf AIDS. 2002 Jul 7–1;14: abstract MoOrB1060.
37.
Spital A. Should all human immunodeficiency virus-infected patients with end-state renal disease be excluded from transplantation: the views of U.S. transplant center. Transplantation. 1998;651:1187–91.CrossRef
38.
Halpern SD, Asch DA, Shaked A. Determinants of transplant surgeon’s willingness to provide organs to patients infected with HBV. HCV or HIV A J Transplant. 2005;5:1319–25.PubMedCrossRef
39.
Halpern SC, Ubel PA, Caplan AL. Solid-organ transplantation in HV infected patients. N Engl J Med. 2002;347:284–7.PubMedCrossRef
40.
Abbott KC, Swanson SJ, Agodoa LYC. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern. J Am Soc Nephro. 2004;15:1633–9.CrossRef
41.
Sawinski D, Wyatt CM, Casagrande L, et al. Factors associated with failure to list HIV positive kidney transplant candidates. A J Transplant. 2009;9:1467–71.CrossRef
42.
Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV 1 infected patient with advanced disease. N Engl J Med. 2003;348:2323–8.PubMedCrossRef
43.
Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant. 2009;28:667–9.PubMedCrossRef
44.
Grossi PA, Righi E, Gasperina DD, et al. Report of four simultaneous pancreas—kidney transplants in HIV positive recipients with favorable outcome. A J Transplant. 2012;12:1039–45.CrossRef
45.
Krishnan A. Stem cell transplantation in HIV infected patients. Cur Opin HIV AIDS. 2009;4:11–5.CrossRef
46.
Izzedine H, Launay-Vacher V, Baumelou A, et al. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int. 2004;66:532–41.PubMedCrossRef
47.
Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and doing modifications in HIV-1 infected liver and kidney transplant recipients. A J Transplant. 2007;7:2816–20.CrossRef
48.
Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus—infected liver and kidney transplant recipients. Transplant Proc. 2009;41:3796–9.PubMedCrossRef
49.
Cousins D, Topping K, Lee V, et al. Successful tacrolimus treatment following renal transplant in a HIV infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Meta Drug Interact. 2011;26:139–41.
50.
Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV–infected transplant patients cotreated with immunosuppressive drugs. A J Transplant. 2009;9:2946–52.
51.
Moreno A, Perez-Elias MJ, Casado JL, et al. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patents after solid organ transplantation. Liver Transpl. 2010;16:530–2.PubMed
52.
Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus infected patients: a pilot safety and efficacy study. Transplantation. 2003;76:370–5.PubMedCrossRef
53.
Qiu J, Terasaki PI, Waki K, et al. HIV positive renal recipients can achieve survival rates similar to those of HIV negative patients. Transplantation. 2006;81:1658–61.PubMedCrossRef
54.
Anil Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV positive patients. Kidney Int. 2005;67:1622–9.CrossRef
55.
Yoon SC, Hurst FP, Jindal RM, et al. Trends in renal transplantation in patients with human immunodeficiency virus infection: an analysis of the United States renal data system. Transplantation. 2011;91:864–8.PubMedCrossRef
56.
•• Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV infected recipients. N Engl J Med. 2010;363:2004–14. The largest prospective trial of 150 renal transplants, demonstrating comparable outcomes to all renal recipients and recipients > 65.PubMedCrossRef
57.
Locke JE, Montgomery RA, Warren DS. Renal transplant in HIV positive patients. Long-term outcomes and risk factors for graft loss. Arch Surg. 2009;144:83–6.PubMedCrossRef
58.
Gruber SA, Doshi MD, Cincotta E, Brown KL, Singh A, et al. Preliminary experience with renal transplantation in HIV + recipients: low acute rejection ad infection rates. Transplantation. 2008;86:269–74.PubMedCrossRef
59.
• Landin L, Rodriguez-Perez JC, Garca-Bello MA. Kidney transplants in HIV positive recipients under HAART. A comprehensive review and meta-analysis of 12 series. Nephro Dial Transplant. 2010;25:3106–15. A meta-analysis providing a broader picture of renal transplantation in the HAART era.CrossRef
60.
Martina MN, Cofan F, Suarez A, et al. Kidney transplantation and waiting list for renal transplantation for human immunodeficiency virus patients. Transplant Proc. 2011;43:2179–81.PubMedCrossRef
61.
• Mazuecos A, Fernandez A, Andres A, et al. HIV infection and renal transplantation. Nephro Dial Transplant. 2011;26:1401–7. A small case-controlled matched cohort of renal transplants with good outcome, but noting the challenges of HCV coinfection.CrossRef
62.
Trullas JC, Mocroft A, Cofan F. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr. 2010;55:582–9.PubMedCrossRef
63.
Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. A J Transplant. 2010;10:2263–9.CrossRef
64.
Mazuecos A, Fernandez A, Andres A, et al. Kidney transplantation outcomes in HIV infection: the European experience. A J Transplant. 2011;11:635–6.CrossRef
65.
Kamath PS, Wiesner RH, Malinchoc M. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.PubMedCrossRef
66.
Ragni MV, Eghtesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005;11:1425–30.PubMedCrossRef
67.
Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–89.PubMedCrossRef
68.
Stock PG. Rapid deterioration of HIV co-infected patients waiting for liver transplantation is not predicted by MELD. Liver Transpl. 2005;11:1315–7.PubMedCrossRef
69.
• Subramanian A, Sulkowski M, Barin B, et al. MELD Score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010;138:159–64. This article validates the use of MELD in HIV patients ending an ongoing debate.PubMedCrossRef
70.
Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239–47.PubMedCrossRef
71.
Norris S, Taylor C, Muiesan P, et al. Outcome of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl. 2004;10:1271–8.PubMedCrossRef
72.
Roland ME, Barin B, Carlson L, et al. HIV-Infected liver and kidney transplant recipients: 1- and 3-Year outcomes. A J Transplant. 2008;8:355–65.CrossRef
73.
Di Benedetto F, Tarantino G, De Ruvo N, et al. University of Modena experience in HIV-positive patients undergoing liver transplantation. Transplant Proc. 2011;43:1114–8.PubMedCrossRef
74.
• Baccarani U, Adani GL, Braganini F, et al. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc. 2011;43:1119–22. A comparison of HIV-positive and -negative liver recipients, showing similar outcomes in Italy.PubMedCrossRef
75.
•• Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. A J Transplantation. 2012;12:1866–76. A large prospective matched study of liver transplants in Spain with higher rejection and mortality in HIV-positive patients. The study delineated factors impacting outcomes.CrossRef
76.
Moreno A, Cervera C, Fortun J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl. 2012;18:70–82.PubMedCrossRef
77.
Douclos-Vallee J-C, Tateo M, Teicher E. Results of liver transplantation in a large cohort of more than 200 HIV infected patients –A monocentric experience. Hepatology. 2011;54(suppl):361A.
78.
Teicher E, Duclos-Vallee J-C. Opportunistic infections after liver transplantation in patients infected with human immunodeficiency virus. Liver Transpl. 2012;18:376–7.PubMedCrossRef
79.
Kemmer NM, Sherman KE. Liver transplantation trends in the HIV population. Dig Dis Sci. 2011;56:3393–8.PubMedCrossRef
80.
• Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systemic review and meta-analysis with synthetic cohort. AIDS. 2011;25:777–86. A meta-analysis of HAART era liver transplantation largely focused on Europe and the U.S., noting excellent HBV liver transplant outcomes and near universal HCV recurrence.PubMedCrossRef
81.
•• Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplant. 2012;18:716–26. HCV outcome in liver transplants from the largest prospective trial outlining factors responsible for decreased survival.CrossRef
82.
Tateo M, Roique-Afonso A-M, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS. 2009;23:1069–76.PubMedCrossRef
83.
• Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. A J Transplant. 2010;10:1268–75. Prospective North American HBV coinfected cohort noting similar very good outcome to HIV-negative liver recipients.CrossRef
84.
Hughes CB, Dickson RC, Krisna M, et al. HCV recurrence in HIV-infected patients after liver transplant. J Int Ass Phys AIDS Care. 2010;9:87–93.CrossRef
85.
De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. A J Transplant. 2006;6:2983–93.CrossRef
86.
Duclos-Vallee J-C, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407–17.PubMedCrossRef
87.
Di Benedetto FD, DeRuvo N, Berretta M, et al. Hepatocellular carcinoma in HIV patients treated by liver transplantation. EJSO. 2008;34:422–7.PubMedCrossRef
88.
Baccarani Um Adani GL, Tavio M, et al. Liver transplantation for Hepatocellular carcinoma: the impact of human immunodeficiency virus infection −21 plus 13. Am Ass Study Liver Dis. 2011; 2138.
89.
• Muller E, Kahn D, Mendelson M. Renal transplantation between HIV positive donors and recipients. N Engl J Med. 2010;362:2336–7. The first case reports of HIV donor and recipient positive renal transplants.PubMedCrossRef
90.
91.
• Boyarsky BJ, Hall EC, Singer AL. Estimating the potential pool of HIV infected deceased organ donors in the United States. A J Transplant. 2011; doi:10.​1111/​j.​1600-6143.​2011.​03506.​X. A study estimating the number of potential HIV-positive donors that could be used for HV-positive recipients, thus helping to alleviate the shortage of organs for transplantation.
92.
Bhagat V, Foont JA, Schiff ER, et al. Spontaneous clearance of hepatitis C virus after liver transplantation in two patients coinfected with hepatitis C virus and human immunodeficiency virus. Liver Transpl. 2008;14:92–5.PubMedCrossRef
93.
Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.PubMedCrossRef
94.
Cobucci RNO, Saconato H, Lima PH, et al. Comparative incidence of cancer in HIV-AIDS patients and transplant recipients. Cancer Epidemiol. 2012;36:e69–73.CrossRef
Metadata
Title
Organ Transplantation and HIV Progress or Success? A Review of Current Status
Author
Alan Taege
Publication date
01-02-2013
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 1/2013
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0309-x

Other articles of this Issue 1/2013

Current Infectious Disease Reports 1/2013 Go to the issue

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What’s New?

HIV/AIDS (R MacArthur, Section Editor)

HCV Enters the Twenty-First Century

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Treatment Options for Hepatitis Delta Virus Infection

Hot Topic

Overview of the XIX International AIDS Conference

Intra-abominal Infections, Hepatitis, and Gastroenteritis (D Bobak, Section Editor)

Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli

HIV/AIDS (R MacArthur, Section Editor)

The Twin Epidemics of Tuberculosis and HIV
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits